Key result
Cytomegalovirus infection (≥500 IU/mL) was not associated with an increased risk of allograft rejection in heart transplant recipients (adjusted OR 0.86; 95% CI 0.55-1.33; P=0.85).
Why the study?
The association between cytomegalovirus infection and allograft rejection after heart transplantation is debated in the era of efficient prophylactic antiviral therapies.
Does cytomegalovirus infection increase the risk of allograft rejection in heart transplant recipients?
Population
384 heart transplant recipients
Comparison
CMV infection vs no CMV infection
Design
Single-center cohort study
Authors
Loading...
CMV-rejection association in HTx remains inconclusive with modern prophylaxis; leaves open whether antiviral strategies modify allograft risk.
Cohort (n=384)
No
Does cytomegalovirus infection increase the risk of allograft rejection in heart transplant recipients?
Odds Ratio: 0.86 (95% CI 0.55–1.33)
p-value: p=0.85
In a contemporary cohort of heart transplant recipients, CMV infection was not associated with an increased risk of allograft rejection.
Boutolleau et al. (2021) conducted a cohort in Heart transplant recipients (n=384). Cytomegalovirus (CMV) infection (CMV load ≥ 500 IU/mL) vs. No CMV infection or CMV load < 500 IU/mL was evaluated on Risk of allograft rejection (cellular rejection ≥ 1R1B, antibody-mediated rejection ≥ pAMR1) (OR 0.86, 95% CI 0.55-1.33, p=0.85). Cytomegalovirus infection (≥500 IU/mL) was not associated with an increased risk of allograft rejection in heart transplant recipients (adjusted OR 0.86; 95% CI 0.55-1.33; P=0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: